Complete Remission After Immunotherapy-Induced Abdominal Tuberculosis in a Patient With Advanced NSCLC Treated With Pembrolizumab: A Case Report

Mariona Riudavets, PhD; Benjamin Wyplosz, PhD; Maria Rosa Ghigna, MD; Angela Botticella, MD; Pamela Abdayem, MD; Pauline Pradere, MD; Ines Kasraoui, MD; Charles Roux, MD; Cécile Le Pechoux, MD; Camilo Garcia, MD; David Planchard, MD, PhD

JTO Clinical and Research Reports (May 2022)

Complete Remission After Immunotherapy-Induced Abdominal Tuberculosis in a Patient With Advanced NSCLC Treated With Pembrolizumab: A Case Report

Mariona Riudavets, PhD,
Benjamin Wyplosz, PhD,
Maria Rosa Ghigna, MD,
Angela Botticella, MD,
Pamela Abdayem, MD,
Pauline Pradere, MD,
Ines Kasraoui, MD,
Charles Roux, MD,
Cécile Le Pechoux, MD,
Camilo Garcia, MD,
David Planchard, MD, PhD

Affiliations

Mariona Riudavets, PhD: Cancer Medicine Department, Gustave Roussy Cancer Campus, Villejuif, France
Benjamin Wyplosz, PhD: Infectious Diseases Department, Hôpital Bicêtre—AP-HP, Le Kremlin Bicêtre, France
Maria Rosa Ghigna, MD: Pathology Department, Gustave Roussy Cancer Campus, Villejuif, France
Angela Botticella, MD: Radiation Oncology Department, Gustave Roussy Cancer Campus, Villejuif, France
Pamela Abdayem, MD: Cancer Medicine Department, Gustave Roussy Cancer Campus, Villejuif, France
Pauline Pradere, MD: Pneumologie Department, Hôpital Marie Lannelongue, Plessis-Robinson, France
Ines Kasraoui, MD: Radiology Department, Gustave Roussy Cancer Campus, Villejuif, France
Charles Roux, MD: Interventional Radiology Department, Gustave Roussy Cancer Campus, Villejuif, France
Cécile Le Pechoux, MD: Radiation Oncology Department, Gustave Roussy Cancer Campus, Villejuif, France
Camilo Garcia, MD: Nuclear Medicine Department, Gustave Roussy Cancer Campus, Villejuif, France
David Planchard, MD, PhD: Cancer Medicine Department, Gustave Roussy Cancer Campus, Villejuif, France; Corresponding author. Address for correspondence: David Planchard, MD, PhD, Department of Cancer Medicine, Gustave Roussy Cancer Campus, 114 Edouard Vaillant Street, F-94800 Villejuif, France.

Journal volume & issue: Vol. 3, no. 5
p. 100319

Abstract

Read online

The use of immune checkpoint inhibitors (ICIs) has drastically transformed the therapeutic landscape in lung cancer. Special focus has been put on immune-related toxicity; however, infections can also seem during ICI treatment. Although rare, tuberculosis (TB) has been increasingly identified after ICIs, and it seems that the programmed cell death protein 1 and programmed death-ligand 1 pathway is directly involved in its pathophysiology. Here, we describe the case of a patient with advanced NSCLC who developed abdominal TB after 32 months of pembrolizumab and who remains in tumor remission 10 months after discontinuation of this drug. Routine screening for latent TB before ICI treatment is advised, with closer collaboration between infectious disease specialists and oncologists.

Published in JTO Clinical and Research Reports

ISSN: 2666-3643 (Online)
Publisher: Elsevier
Country of publisher: United States
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.journals.elsevier.com/jto-clinical-and-research-reports/

About the journal

Abstract

Keywords